Research Analysts Issue Forecasts for Surmodics Q2 Earnings

Surmodics, Inc. (NASDAQ:SRDX) – Equities researchers at Zacks Research raised their Q2 2025 earnings estimates for Surmodics in a report issued on Tuesday, January 28th. Zacks Research analyst D. Dey now forecasts that the company will earn ($0.05) per share for the quarter, up from their previous estimate of ($0.08). The consensus estimate for Surmodics’ current full-year earnings is $0.19 per share. Zacks Research also issued estimates for Surmodics’ Q4 2025 earnings at $0.21 EPS and Q3 2026 earnings at $0.20 EPS.

Other equities analysts have also issued research reports about the stock. Needham & Company LLC reiterated a “hold” rating on shares of Surmodics in a report on Thursday. StockNews.com initiated coverage on Surmodics in a report on Sunday, January 26th. They set a “hold” rating on the stock. Five research analysts have rated the stock with a hold rating, According to data from MarketBeat, Surmodics presently has a consensus rating of “Hold” and an average target price of $50.00.

Surmodics Stock Down 0.8 %

NASDAQ:SRDX opened at $35.48 on Friday. The company has a current ratio of 3.96, a quick ratio of 3.22 and a debt-to-equity ratio of 0.25. Surmodics has a one year low of $25.17 and a one year high of $42.44. The firm’s 50 day simple moving average is $38.81 and its 200 day simple moving average is $39.21.

Surmodics (NASDAQ:SRDX) last posted its earnings results on Thursday, February 6th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.04. Surmodics had a negative return on equity of 3.79% and a negative net margin of 9.15%.

Insider Activity

In other news, CFO Timothy J. Arens sold 7,009 shares of the business’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $39.44, for a total value of $276,434.96. Following the transaction, the chief financial officer now directly owns 70,350 shares of the company’s stock, valued at $2,774,604. The trade was a 9.06 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 8.90% of the company’s stock.

Institutional Investors Weigh In On Surmodics

Hedge funds have recently added to or reduced their stakes in the business. Rhumbline Advisers grew its position in shares of Surmodics by 4.4% during the 4th quarter. Rhumbline Advisers now owns 20,250 shares of the company’s stock worth $802,000 after buying an additional 861 shares during the period. Modus Advisors LLC bought a new position in Surmodics during the fourth quarter worth $40,000. Quest Partners LLC boosted its stake in Surmodics by 107,100.0% during the third quarter. Quest Partners LLC now owns 1,072 shares of the company’s stock worth $42,000 after acquiring an additional 1,071 shares in the last quarter. SG Americas Securities LLC grew its holdings in Surmodics by 22.1% in the fourth quarter. SG Americas Securities LLC now owns 6,940 shares of the company’s stock worth $275,000 after purchasing an additional 1,255 shares during the period. Finally, R Squared Ltd bought a new stake in Surmodics in the fourth quarter valued at $55,000. 96.63% of the stock is currently owned by institutional investors.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).